Drug interactions
Encorafenib + Rolapitant
Severity: Minor
Encorafenib and Rolapitant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, but rolapitant is not a significant CYP3A4 substrate, and rolapitant's own CYP3A4 interaction profile is limited. Net effect on rolapitant is unclear.
What this interaction means in plain words
Encorafenib and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Encorafenib belongs to Oncology; Rolapitant belongs to Gastrointestinal Tract.
Why it happens
Encorafenib has mixed CYP3A4 induction and inhibition, and the net effect on rolapitant exposure is not established.
What to do
No routine adjustment; monitor antiemetic efficacy and tolerability.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Rolapitant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Rolapitant
- Pimozide + Rolapitant Contraindicated
- Rolapitant + Thioridazine Contraindicated
- Atomoxetine + Rolapitant Major
- Deutetrabenazine + Rolapitant Major
- Eliglustat + Rolapitant Major
- Flecainide + Rolapitant Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Rolapitant?
MediHelp rates the interaction as minor. Encorafenib and Rolapitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Encorafenib both inhibits and induces CYP3A4, but rolapitant is not a significant CYP3A4 substrate, and rolapitant's own CYP3A4 interaction profile is limited. Net effect on rolapitant is unclear.
How serious is the interaction between Encorafenib and Rolapitant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment; monitor antiemetic efficacy and tolerability.
What other medicines interact with Rolapitant?
MediHelp also lists interactions of Rolapitant with, for example, Pimozide, Thioridazine, Atomoxetine. The full list is on the Rolapitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
